Protagonist Therapeutics: Proprietary peptide technology platform to develop oral targeted therapy-based drugs that work by blocking biological pathways currently targeted by marketed injectable antibody drugs, and injectables for rare diseases. PTG-300 injectable hepcidin mimetic PTG-300 Ph 2 beta-thalassemia initial results expected 4Q19; PN-943 oral GI-restricted alpha-4-beta-7 antagonist Ph 2 in ulcerative colitis to begin in early 2020; and PTG-200, partnered w/ Janssen, oral GI-restricted IL-23R antagonist to begin Ph 2 Crohn’s disease study in 4Q19.
Based in...
Clinical Stage
Phase l or ll
Disease Space
Anti-inflammatory, Gastrointestinal, Hematology, Rare Disease
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Platform Technology
521 Cottonwood Drive
Suite 100
Milpitas, CA 95035
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.